Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 1.81
REGN's Cash-to-Debt is ranked lower than
73% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. REGN: 1.81 )
Ranked among companies with meaningful Cash-to-Debt only.
REGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.57  Med: 1.95 Max: No Debt
Current: 1.81
Equity-to-Asset 0.68
REGN's Equity-to-Asset is ranked higher than
52% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. REGN: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
REGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.65 Max: 0.95
Current: 0.68
0.18
0.95
Debt-to-Equity 0.13
REGN's Debt-to-Equity is ranked higher than
68% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. REGN: 0.13 )
Ranked among companies with meaningful Debt-to-Equity only.
REGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.18 Max: 3.2
Current: 0.13
0
3.2
Debt-to-EBITDA 0.38
REGN's Debt-to-EBITDA is ranked higher than
81% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. REGN: 0.38 )
Ranked among companies with meaningful Debt-to-EBITDA only.
REGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.55  Med: 0.28 Max: 0.92
Current: 0.38
-2.55
0.92
Interest Coverage 102.35
REGN's Interest Coverage is ranked lower than
73% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 102.35 )
Ranked among companies with meaningful Interest Coverage only.
REGN' s Interest Coverage Range Over the Past 10 Years
Min: 10.1  Med: 22.05 Max: 184.95
Current: 102.35
10.1
184.95
Piotroski F-Score: 7
Altman Z-Score: 13.24
Beneish M-Score: -2.66
WACC vs ROIC
12.19%
29.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 32.29
REGN's Operating Margin % is ranked higher than
94% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. REGN: 32.29 )
Ranked among companies with meaningful Operating Margin % only.
REGN' s Operating Margin % Range Over the Past 10 Years
Min: -91.55  Med: 3.92 Max: 35.3
Current: 32.29
-91.55
35.3
Net Margin % 22.05
REGN's Net Margin % is ranked higher than
90% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. REGN: 22.05 )
Ranked among companies with meaningful Net Margin % only.
REGN' s Net Margin % Range Over the Past 10 Years
Min: -84.46  Med: -2.95 Max: 54.43
Current: 22.05
-84.46
54.43
ROE % 24.67
REGN's ROE % is ranked higher than
95% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. REGN: 24.67 )
Ranked among companies with meaningful ROE % only.
REGN' s ROE % Range Over the Past 10 Years
Min: -43.76  Med: -0.78 Max: 86.68
Current: 24.67
-43.76
86.68
ROA % 16.07
REGN's ROA % is ranked higher than
95% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. REGN: 16.07 )
Ranked among companies with meaningful ROA % only.
REGN' s ROA % Range Over the Past 10 Years
Min: -18.38  Med: 0.35 Max: 44.08
Current: 16.07
-18.38
44.08
ROC (Joel Greenblatt) % 52.45
REGN's ROC (Joel Greenblatt) % is ranked higher than
92% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. REGN: 52.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
REGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -173.81  Med: 7.5 Max: 61.97
Current: 52.45
-173.81
61.97
3-Year Revenue Growth Rate 30.20
REGN's 3-Year Revenue Growth Rate is ranked higher than
80% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. REGN: 30.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
REGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -25  Med: 24.1 Max: 81.1
Current: 30.2
-25
81.1
3-Year EBITDA Growth Rate 20.70
REGN's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. REGN: 20.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
REGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56.7  Med: 22.7 Max: 122.8
Current: 20.7
-56.7
122.8
3-Year EPS without NRI Growth Rate 27.40
REGN's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. REGN: 27.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
REGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.3  Med: -5.8 Max: 86.3
Current: 27.4
-38.3
86.3
GuruFocus has detected 3 Warning Signs with Regeneron Pharmaceuticals Inc REGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» REGN's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

REGN Guru Trades in Q4 2016

Jim Simons 250,560 sh (New)
Manning & Napier Advisors, Inc 440,316 sh (New)
Ken Fisher 715 sh (+15.32%)
Vanguard Health Care Fund 3,309,690 sh (+0.93%)
Ron Baron 4,969 sh (+0.91%)
Eaton Vance Worldwide Health Sciences Fund 60,662 sh (unchged)
Mario Gabelli Sold Out
George Soros Sold Out
Paul Tudor Jones Sold Out
Frank Sands 2,302,802 sh (-7.79%)
Joel Greenblatt 12,096 sh (-51.12%)
» More
Q1 2017

REGN Guru Trades in Q1 2017

Steven Cohen 70,000 sh (New)
Paul Tudor Jones 600 sh (New)
Ron Baron 6,429 sh (+29.38%)
Frank Sands 2,933,444 sh (+27.39%)
Ken Fisher 806 sh (+12.73%)
Vanguard Health Care Fund 3,635,985 sh (+9.86%)
Joel Greenblatt Sold Out
Jim Simons 232,076 sh (-7.38%)
Manning & Napier Advisors, Inc 376,003 sh (-14.61%)
Eaton Vance Worldwide Health Sciences Fund 45,415 sh (-25.13%)
» More
Q2 2017

REGN Guru Trades in Q2 2017

Mario Gabelli 492 sh (New)
Ken Fisher 1,411 sh (+75.06%)
Ron Baron 7,061 sh (+9.83%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Frank Sands 2,793,959 sh (-4.75%)
Vanguard Health Care Fund 3,255,810 sh (-10.46%)
Manning & Napier Advisors, Inc 298,778 sh (-20.54%)
Eaton Vance Worldwide Health Sciences Fund 39,536 sh (-12.95%)
» More
2017

REGN Guru Trades in 2017

Spiros Segalas 520,590 sh (+94.62%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -10.46%0.33%$366.06 - $526.53 $ 442.562%3,255,810
Ron Baron 2017-06-30 Add 9.83%$366.06 - $526.53 $ 442.562%7,061
Ken Fisher 2017-06-30 Add 75.06%$366.06 - $526.53 $ 442.562%1,411
Mario Gabelli 2017-06-30 New Buy$366.06 - $526.53 $ 442.562%492
Vanguard Health Care Fund 2017-03-31 Add 9.86%0.28%$340.75 - $397.8 $ 442.5619%3,635,985
Ron Baron 2017-03-31 Add 29.38%$340.75 - $397.8 $ 442.5619%6,429
Ken Fisher 2017-03-31 Add 12.73%$340.75 - $397.8 $ 442.5619%806
Joel Greenblatt 2017-03-31 Sold Out 0.06%$340.75 - $397.8 $ 442.5619%0
Vanguard Health Care Fund 2016-12-31 Add 0.93%0.03%$336.01 - $444.52 $ 442.5616%3,309,690
Joel Greenblatt 2016-12-31 Reduce -51.12%0.07%$336.01 - $444.52 $ 442.5616%12,096
Ron Baron 2016-12-31 Add 0.91%$336.01 - $444.52 $ 442.5616%4,969
Ken Fisher 2016-12-31 Add 15.32%$336.01 - $444.52 $ 442.5616%715
George Soros 2016-12-31 Sold Out 0.02%$336.01 - $444.52 $ 442.5616%0
Mario Gabelli 2016-12-31 Sold Out $336.01 - $444.52 $ 442.5616%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:LSE:SHP, ASX:CSL, NAS:VRTX, NAS:ALXN, XSWX:ATLN, NAS:BIIB, NAS:INCY, XKRX:207940, XMCE:GRF.P, NAS:BMRN, XKRX:068270, SZSE:002252, OCSE:NZYM B, OCSE:GEN, XBRU:UCB, NAS:ALNY, NAS:KITE, NAS:JAZZ, NAS:ALKS, HKSE:01177 » details
Traded in other countries:REGN.Austria, RGO.Germany, REGN.Mexico, REGN.Switzerland, 0R2M.UK,
Headquarter Location:USA
Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has five marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis; and Arcalyst in CAPS. Regeneron is also developing monoclonal antibodies with Sanofi in rheumatoid arthritis, asthma, and cancer.

Guru Investment Theses on Regeneron Pharmaceuticals Inc

Baron Funds Comments on Regeneron Pharmaceuticals - May 23, 2016

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017
Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens
Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma

Ratios

vs
industry
vs
history
PE Ratio 44.45
REGN's PE Ratio is ranked lower than
66% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. REGN: 44.45 )
Ranked among companies with meaningful PE Ratio only.
REGN' s PE Ratio Range Over the Past 10 Years
Min: 22.84  Med: 63.16 Max: 169.6
Current: 44.45
22.84
169.6
Forward PE Ratio 26.95
REGN's Forward PE Ratio is ranked lower than
54% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. REGN: 26.95 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 44.45
REGN's PE Ratio without NRI is ranked lower than
64% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. REGN: 44.45 )
Ranked among companies with meaningful PE Ratio without NRI only.
REGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.84  Med: 63.16 Max: 169.6
Current: 44.45
22.84
169.6
Price-to-Owner-Earnings 118.16
REGN's Price-to-Owner-Earnings is ranked lower than
87% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. REGN: 118.16 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
REGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 47.71  Med: 105.15 Max: 1511.41
Current: 118.16
47.71
1511.41
PB Ratio 8.59
REGN's PB Ratio is ranked lower than
78% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. REGN: 8.59 )
Ranked among companies with meaningful PB Ratio only.
REGN' s PB Ratio Range Over the Past 10 Years
Min: 2.47  Med: 9.61 Max: 26.41
Current: 8.59
2.47
26.41
PS Ratio 9.79
REGN's PS Ratio is ranked higher than
54% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. REGN: 9.79 )
Ranked among companies with meaningful PS Ratio only.
REGN' s PS Ratio Range Over the Past 10 Years
Min: 3.69  Med: 11.44 Max: 28.22
Current: 9.79
3.69
28.22
Price-to-Free-Cash-Flow 52.37
REGN's Price-to-Free-Cash-Flow is ranked lower than
70% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. REGN: 52.37 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
REGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 32.37  Med: 87.6 Max: 1910.91
Current: 52.37
32.37
1910.91
Price-to-Operating-Cash-Flow 37.88
REGN's Price-to-Operating-Cash-Flow is ranked lower than
65% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. REGN: 37.88 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
REGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.64  Med: 49.6 Max: 559.41
Current: 37.88
21.64
559.41
EV-to-EBIT 27.48
REGN's EV-to-EBIT is ranked lower than
55% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. REGN: 27.48 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.7  Med: -6.65 Max: 1948.5
Current: 27.48
-108.7
1948.5
EV-to-EBITDA 25.52
REGN's EV-to-EBITDA is ranked lower than
56% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. REGN: 25.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
REGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -141.9  Med: -7.45 Max: 387.4
Current: 25.52
-141.9
387.4
EV-to-Revenue 8.95
REGN's EV-to-Revenue is ranked higher than
59% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. REGN: 8.95 )
Ranked among companies with meaningful EV-to-Revenue only.
REGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.2  Med: 11.05 Max: 26.7
Current: 8.95
2.2
26.7
Shiller PE Ratio 168.59
REGN's Shiller PE Ratio is ranked lower than
89% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. REGN: 168.59 )
Ranked among companies with meaningful Shiller PE Ratio only.
REGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 165.16  Med: 354.72 Max: 4161.1
Current: 168.59
165.16
4161.1
Current Ratio 3.75
REGN's Current Ratio is ranked lower than
53% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. REGN: 3.75 )
Ranked among companies with meaningful Current Ratio only.
REGN' s Current Ratio Range Over the Past 10 Years
Min: 2.17  Med: 6.43 Max: 55.65
Current: 3.75
2.17
55.65
Quick Ratio 3.21
REGN's Quick Ratio is ranked lower than
56% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. REGN: 3.21 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.17  Med: 6.32 Max: 55.65
Current: 3.21
2.17
55.65
Days Inventory 496.68
REGN's Days Inventory is ranked lower than
94% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. REGN: 496.68 )
Ranked among companies with meaningful Days Inventory only.
REGN' s Days Inventory Range Over the Past 10 Years
Min: 97.79  Med: 170.76 Max: 780.78
Current: 496.68
97.79
780.78
Days Sales Outstanding 99.01
REGN's Days Sales Outstanding is ranked lower than
71% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. REGN: 99.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.13  Med: 93.08 Max: 157.07
Current: 99.01
23.13
157.07
Days Payable 180.56
REGN's Days Payable is ranked higher than
82% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. REGN: 180.56 )
Ranked among companies with meaningful Days Payable only.
REGN' s Days Payable Range Over the Past 10 Years
Min: 131.02  Med: 172.72 Max: 2718.58
Current: 180.56
131.02
2718.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
REGN's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. REGN: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
REGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.9  Med: -7.25 Max: -2.1
Current: -2.1
-17.9
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 37.19
REGN's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. REGN: 37.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
REGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.61  Med: 8.38 Max: 157.38
Current: 37.19
1.61
157.38
Price-to-Tangible-Book 8.59
REGN's Price-to-Tangible-Book is ranked lower than
70% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. REGN: 8.59 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
REGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.52 Max: 22
Current: 8.59
0.84
22
Price-to-Intrinsic-Value-Projected-FCF 4.91
REGN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
61% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. REGN: 4.91 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
REGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.44  Med: 15.52 Max: 206.31
Current: 4.91
4.44
206.31
Price-to-Median-PS-Value 0.86
REGN's Price-to-Median-PS-Value is ranked higher than
60% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. REGN: 0.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
REGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.07 Max: 4.67
Current: 0.86
0.19
4.67
Price-to-Peter-Lynch-Fair-Value 1.78
REGN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
51% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. REGN: 1.78 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
REGN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.87  Med: 1.97 Max: 2.58
Current: 1.78
0.87
2.58
Price-to-Graham-Number 4.12
REGN's Price-to-Graham-Number is ranked lower than
69% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. REGN: 4.12 )
Ranked among companies with meaningful Price-to-Graham-Number only.
REGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.33  Med: 5.5 Max: 10.19
Current: 4.12
1.33
10.19
Earnings Yield (Greenblatt) % 3.67
REGN's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. REGN: 3.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
REGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19  Med: -1 Max: 3.67
Current: 3.67
-19
3.67
Forward Rate of Return (Yacktman) % 53.66
REGN's Forward Rate of Return (Yacktman) % is ranked higher than
96% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. REGN: 53.66 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
REGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8  Med: -1.4 Max: 53.7
Current: 53.66
-8
53.7

More Statistics

Revenue (TTM) (Mil) $5,236.06
EPS (TTM) $ 9.96
Beta1.66
Short Percentage of Float2.99%
52-Week Range $325.35 - 543.55
Shares Outstanding (Mil)107.15

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 5,720 6,212 6,913 7,734
EPS ($) 14.86 16.56 19.54 22.74
EPS without NRI ($) 14.86 16.56 19.54 22.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
17.16%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}